BDSX logo

BDSX
Biodesix Inc

1,650
Mkt Cap
$111.99M
Volume
27,942.00
52W High
$20.21
52W Low
$3.44
PE Ratio
-2.34
BDSX Fundamentals
Price
$11.08
Prev Close
$10.98
Open
$10.95
50D MA
$14.31
Beta
0.50
Avg. Volume
57,979.91
EPS (Annual)
-$4.67
P/B
-37.10
Rev/Employee
$264,967.07
$105.11
Loading...
Loading...
News
all
press releases
Biodesix (BDSX) to Release Earnings on Monday
Biodesix (NASDAQ:BDSX) will be releasing its Q1 2026 earnings after the market closes on Monday, May 4. (View Earnings Report at...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages
Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have received an average rating of "Moderate Buy" from the six ratings firms that are currently covering the company, Marketbeat Ratings...
MarketBeat·8d ago
News Placeholder
Biodesix Becomes Oversold (BDSX)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets·11d ago
News Placeholder
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
Here is how Aura Biosciences, Inc. (AURA) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Zacks·11d ago
News Placeholder
LifeMD (LFMD) Soars 23.7%: Is Further Upside Left in the Stock?
LifeMD (LFMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·12d ago
News Placeholder
Here's Why You Should Add DexCom Stock to Your Portfolio Now
DexCom's expanding CGM market, G7 rollout, and global growth momentum position it for gains, despite pricing pressure and near-term margin risks.
Zacks·17d ago
News Placeholder
MDLN Gets FDA Warning for Quality Lapses in Angiographic Syringes
MDLN faces FDA warning over cGMP lapses in angiographic syringes, citing weak quality controls, CAPA gaps and design flaws despite escalating share price.
Zacks·19d ago
News Placeholder
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study
PLSE begins patient enrollment in NANOPULSE-AF pivotal study, advancing its NPS tech toward potential AF treatment approval and entry into a large cardiac market.
Zacks·20d ago
News Placeholder
Aberdeen Group plc Takes $1.78 Million Position in Biodesix, Inc. $BDSX
Aberdeen Group plc purchased a new stake in shares of Biodesix, Inc. (NASDAQ:BDSX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission...
MarketBeat·24d ago
News Placeholder
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DVA rides on EPS growth and early IKC profitability, but flat treatment volumes and reimbursement risks raise questions about sustaining momentum.
Zacks·24d ago
<
1
2
...
>

Latest BDSX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.